Why the study?
In patients with a history of idiopathic venous thromboembolism (VTE), is plasma D-dimer helpful in evaluating the risk of recurrence to determine whether oral anticoagulation therapy (OAT) is appropriate beyond the standard 3-6 months of therapy?
In patients with a history of idiopathic venous thromboembolism (VTE), is plasma D-dimer helpful in evaluating the risk of recurrence to determine whether oral anticoagulation therapy (OAT) is appropriate beyond the standard 3-6 months of therapy?
Plasma D-dimer testing one month after stopping standard anticoagulation for idiopathic VTE is a useful tool to stratify recurrence risk and guide the decision to resume or permanently discontinue therapy.
Supports D-dimer-guided OAT decisions in idiopathic VTE; leaves open randomized validation before practice change.
In patients with a history of idiopathic venous thromboembolism (VTE), is plasma D-dimer helpful in evaluating the risk of recurrence to determine whether oral anticoagulation therapy (OAT) is appropriate beyond the standard 3-6 months of therapy?
No takes yet. Share an insight, caveat, or question.
Knabe et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: